LON:DOCS Dr. Martens (DOCS) Share Price, News & Analysis GBX 56.25 -1.85 (-3.18%) As of 11:53 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock About Dr. Martens Stock (LON:DOCS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dr. Martens alerts:Sign Up Key Stats Today's Range 56.10▼ 60.9050-Day Range 47.98▼ 61.0552-Week Range 43.02▼ 93.25Volume454,636 shsAverage Volume2.30 million shsMarket Capitalization£546.05 millionP/E Ratio7.97Dividend Yield5.33%Price TargetGBX 6,000Consensus RatingHold Company OverviewDr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories.Read More… Dr. Martens Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreDOCS MarketRank™: Dr. Martens scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingDr. Martens has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDr. Martens has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Martens' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Martens is 7.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Martens is 7.97, which means that it is trading at a less expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 89.50.Price to Earnings Growth RatioDr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Martens has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DOCS. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Martens pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Martens does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Martens is 42.53%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Dr. Martens' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DOCS. News and Social Media1.6 / 5News Sentiment-0.19 News SentimentDr. Martens has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Consumer Cyclical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dr. Martens this week, compared to 2 articles on an average week.Search Interest23 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Dr. Martens insiders have bought more of their company's stock than they have sold. Specifically, they have bought £17,927.71 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 4.36% of the stock of Dr. Martens is held by insiders.Percentage Held by Institutions69.53% of the stock of Dr. Martens is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dr. Martens' insider trading history. Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Martens and its competitors with MarketBeat's FREE daily newsletter. Email Address DOCS Stock News HeadlinesRoyal Bank of Canada Issues Pessimistic Forecast for Dr. Martens (LON:DOCS) Stock PriceMay 21 at 1:31 AM | americanbankingnews.comThis FTSE 250 icon’s been very quiet. What’s going on?May 20 at 6:07 AM | msn.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.May 21, 2025 | Timothy Sykes (Ad)Doc Martens rare deal drops price to just $85: ‘I don’t want to take them off’May 9, 2025 | msn.comDoc Martens sale is so good you’ll regret missing out - Prices start at $64.99May 8, 2025 | msn.comBest selling Doc Martens are under $100 right nowMay 8, 2025 | msn.comIs The Market Rewarding Dr. Martens plc (LON:DOCS) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?May 7, 2025 | finance.yahoo.comBestselling Dr. Martens sandals that are 'so comfy from day one' are slashed by £42April 26, 2025 | mirror.co.ukSee More Headlines DOCS Stock Analysis - Frequently Asked Questions How have DOCS shares performed this year? Dr. Martens' stock was trading at GBX 72.20 at the beginning of the year. Since then, DOCS shares have decreased by 22.1% and is now trading at GBX 56.25. View the best growth stocks for 2025 here. How were Dr. Martens' earnings last quarter? Dr. Martens plc (LON:DOCS) released its earnings results on Thursday, November, 28th. The company reported ($1.30) earnings per share for the quarter. Dr. Martens had a trailing twelve-month return on equity of 18.91% and a net margin of 7.89%. Read the conference call transcript. How do I buy shares of Dr. Martens? Shares of DOCS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Dr. Martens own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Martens investors own include boohoo group (BOO), Aston Martin Lagonda Global (AML), ASOS (ASC), Vodafone Group Public (VOD), JD Sports Fashion (JD), Legal & General Group (LGEN) and Lloyds Banking Group (LLOY). Company Calendar Last Earnings11/28/2024Record date for 4/8 Dividend3/06/2025Ex-Dividend for 4/8 Dividend3/06/2025Dividend Payable4/08/2025Today5/21/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorConsumer Cyclical Industry Footwear & Accessories Sub-IndustryComputer Software Current SymbolLON:DOCS CIKN/A Webwww.drmartensplc.com Phone44 12 1415 7047FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 6,000 High Stock Price TargetGBX 6,000 Low Stock Price TargetGBX 6,000 Potential Upside/Downside+10,566.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 7.05 Trailing P/E Ratio7.97 Forward P/E Ratio21.79 P/E Growth6.4Net Income£68.97 million Net Margins7.89% Pretax MarginN/A Return on Equity18.91% Return on Assets8.12% Debt Debt-to-Equity Ratio127.27 Current Ratio2.85 Quick Ratio1.13 Sales & Book Value Annual Sales£874.20 million Price / Sales0.62 Cash FlowGBX 3.94 per share Price / Cash Flow14.29 Book ValueGBX 37.80 per share Price / Book1.49Miscellaneous Outstanding Shares970,763,405Free FloatN/AMarket Cap£546.05 million OptionableNot Optionable Beta0.11 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (LON:DOCS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Martens plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Martens With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.